Bio Rad Laboratories: Initiation of Coverage – Unveiling the Future – Next-Gen Products That Will Skyrocket Your Portfolio! 

This is our first report on life science research and clinical diagnostic products manufacturer, Bio[1]Rad Laboratories. The company’s results exhibit resilience with substantial room for improvements and growth in the coming years. Bio-Rad’s FY 2023 net sales of $2.671 billion reflect a decrease by 4.7% on a reported basis as compared to 2022. Considering that COVID-related sales for that year were about $4 million compared to $109 million in 2022, the core year-over-year revenue remained effectively flat on a currency-neutral basis, demonstrating that the company has a solid fundamental performance outside of pandemic-related sales.